CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Millions		Total		Common Stock	[1]	Treasury Stock	[1]	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Equity Attributable to Noncontrolling Interests	Share Repurchase Program
Treasury Stock, Common, Shares		29,300,000
Common stock, shares outstanding		501,900,000
Beginning balance at Dec. 31, 2021		$ 4,544		$ 5		$ (2,952)		$ 1,068	$ 7,186	$ (764)	$ 1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)		2,111							2,114		(3)
Other comprehensive loss		$ (53)	[2]							(53)	0
Stock-based compensation		0
Treasury Stock, Shares, Acquired		700,000										9,500,000
Share-based compensation awards	[3]	$ 23				7		17	(1)
Share repurchase program		0
Treasury stock acquired	[4]	$ (1,594)				(1,594)
Employee benefit plan contribution from Pfizer Inc.	[5]	3						3
Dividends declared		(631)							(631)
Ending balance at Dec. 31, 2022		$ 4,403		5		(4,539)		1,088	8,668	(817)	(2)
Treasury Stock, Common, Shares		38,100,000
Common stock, shares outstanding		501,900,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)		$ 2,340							2,344		(4)
Other comprehensive loss		$ (22)	[2]							(22)	0
Stock-based compensation		0
Treasury Stock, Shares, Acquired		900,000										6,300,000
Share-based compensation awards	[3]	$ 88				44		45	(1)
Share repurchase program		0
Treasury stock acquired	[4]	$ (1,102)				(1,102)
Dividends declared		(716)							(716)
Ending balance at Dec. 31, 2023		$ 4,991		5		(5,597)		1,133	10,295	(839)	(6)
Treasury Stock, Common, Shares		43,523,885
Common stock, shares outstanding		501,891,243
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)		$ 2,496									10
Other comprehensive loss		$ (101)	[2]							(101)	0
Noncontrolling Interest, Decrease from Deconsolidation	[5]										$ (4)
Treasury Stock, Shares, Acquired		600,000										10,500,000
Consolidation of a noncontrolling interest	[5]	$ (4)
Share-based compensation awards	[3]	65				17		49	(1)
Treasury stock acquired	[4]	(1,865)				(1,865)
Dividends declared		(812)							(812)
Ending balance at Dec. 31, 2024		$ 4,770		$ 5		$ (7,445)		$ 1,182	$ 11,968	$ (940)
Treasury Stock, Common, Shares		53,418,170
Common stock, shares outstanding		501,891,243

[1] $4,050 

[2] Presented net of reclassification adjustments, which are not material in any period presented. Reclassification adjustments related to benefit plans are generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, general and administrative expenses, and/or Research and development expenses, as appropriate, in the Consolidated Statements of Income.

[3] Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 15. Share-based Payments and Note 16. Stockholders' Equity.

[4] Reflects the acquisition of treasury shares in connection with the share repurchase program. For 2024 and 2023, includes excise tax accrued on net share repurchases. For additional information, see Note 16. Stockholders' Equity.

[5] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans. See Note 14. Benefit Plans.